The lancet oncology
-
The lancet oncology · Aug 2014
Multicenter Study Observational StudySurvival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study.
More effective treatments have become available for haematological malignancies from the early 2000s, but few large-scale population-based studies have investigated their effect on survival. Using EUROCARE data, and HAEMACARE morphological groupings, we aimed to estimate time trends in population-based survival for 11 lymphoid and myeloid malignancies in 20 European countries, by region and age. ⋯ Compagnia di San Paolo, Fondazione Cariplo, European Commission, and Italian Ministry of Health.
-
The lancet oncology · Aug 2014
Comparative StudyCombination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Present first-line therapy for diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Ibrutinib, a novel oral Bruton's tyrosine kinase inhibitor, has shown single-drug activity in relapsed or refractory B-cell malignancies. We investigated the safety and efficacy of ibrutinib in combination with R-CHOP for patients with previously untreated CD20-positive B-cell non-Hodgkin lymphoma. ⋯ Janssen.
-
The lancet oncology · Aug 2014
Randomized Controlled Trial Multicenter StudyMEK1/2 inhibition delays progression of uveal melanoma.
-
The lancet oncology · Aug 2014
Practice GuidelineEANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.
This guideline provides recommendations for diagnostic and therapeutic procedures for patients with malignant gliomas. We differentiate evidence-based standards from reasonable options or non-evidence-based measures that should no longer be considered. ⋯ It should serve as a guideline for all professionals involved in the diagnostics and care of glioma patients and also as a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in Europe. Implementation of the recommendations summarised here will need interdisciplinary structures of care for patients with brain tumours and structured processes of diagnostic and therapeutic procedures.
-
The lancet oncology · Aug 2014
Randomized Controlled Trial Comparative StudyPoor results for everolimus in patients with liver cancer.